OMY Stock Overview
Synairgen plc discovers and develops drugs for respiratory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Synairgen plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.03 |
| 52 Week High | UK£0.098 |
| 52 Week Low | UK£0.006 |
| Beta | -2.21 |
| 1 Month Change | 22.00% |
| 3 Month Change | 154.17% |
| 1 Year Change | -40.43% |
| 3 Year Change | -98.72% |
| 5 Year Change | n/a |
| Change since IPO | -98.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| OMY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.2% | 2.1% | -0.1% |
| 1Y | -40.4% | -9.7% | 7.4% |
Return vs Industry: OMY underperformed the German Biotechs industry which returned -9.7% over the past year.
Return vs Market: OMY underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| OMY volatility | |
|---|---|
| OMY Average Weekly Movement | 120.2% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OMY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OMY's weekly volatility has increased from 84% to 120% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 36 | Richard Marsden | www.synairgen.com |
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc Fundamentals Summary
| OMY fundamental statistics | |
|---|---|
| Market cap | €6.37m |
| Earnings (TTM) | -€8.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs OMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMY income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£6.92m |
| Earnings | -UK£6.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OMY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 18:04 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Synairgen plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Cavendish |
| Mark Brewer | Cavendish |
| Paul Cuddon | Numis Securities Ltd. |